{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:30:28Z","timestamp":1789659028288,"version":"4.0.1"},"reference-count":158,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Silesia","award":["BNW-1-050\/N\/6\/O"],"award-info":[{"award-number":["BNW-1-050\/N\/6\/O"]}],"id":[{"id":"https:\/\/ror.org\/005k7hp45","id-type":"ROR","asserted-by":"crossref"}]},{"award":["BNW-1-050\/N\/6\/O"],"award-info":[{"award-number":["BNW-1-050\/N\/6\/O"]}],"id":[{"id":"https:\/\/ror.org\/005k7hp45","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>KRAS is one of the most frequently altered oncogenes in non-small cell lung cancer (NSCLC), playing a pivotal role in tumour initiation, progression, and therapeutic response. This review summarises the current understanding of the molecular mechanisms underlying KRAS-driven NSCLC, with particular emphasis on signalling pathways, genetic alterations, and their clinical implications. We discuss the spectrum of KRAS mutations and polymorphisms, highlighting their impact on disease biology, prognosis, and treatment outcomes. In addition, the review explores the contribution of epigenetic regulation to KRAS-mediated oncogenesis, focusing on the roles of non-coding RNAs, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), as well as post-translational modifications of the KRAS protein, such as methylation, phosphorylation, ubiquitination, nitrosylation, and acetylation. Recent advances in the development of KRAS-targeted therapies are presented, including mutation-specific and pan-KRAS inhibitors. Furthermore, we discuss combination treatment approaches designed to overcome intrinsic and acquired resistance by targeting complementary signalling pathways or modulating the tumour microenvironment. Collectively, this review highlights the complexity of KRAS biology in NSCLC and underscores the importance of integrating molecular, epigenetic, and therapeutic insights to advance precision medicine and improve clinical outcomes.<\/jats:p>","DOI":"10.3390\/ijms27188194","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:16:48Z","timestamp":1789460208000},"page":"8194","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Role of KRAS in Non-Small Cell Lung Cancer: From Molecular Background to Precision Medicine"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3335-2403","authenticated-orcid":false,"given":"Jadwiga","family":"Ga\u017adzicka","sequence":"first","affiliation":[{"name":"Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 19 Jordana St., 41-808 Zabrze, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0042-5856","authenticated-orcid":false,"given":"Karolina","family":"Go\u0142\u0105bek","sequence":"additional","affiliation":[{"name":"Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 19 Jordana St., 41-808 Zabrze, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"ref_1","first-page":"e70090","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","volume":"76","author":"Sung","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ghosh, D.D., McDonald, H., Dutta, R., Krishnan, K., Thilakan, J., Paul, M.K., Arya, N., Rao, M., and Rangnekar, V.M. (2024). Prognostic Indicators for Precision Treatment of Non-Small Cell Lung Carcinoma. Cells, 13.","DOI":"10.3390\/cells13211785"},{"key":"ref_3","unstructured":"Clark, S.B., and Alsubait, S. (2026, June 21). Non\u2013Small Cell Lung Cancer, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK562307\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e32899","DOI":"10.1097\/MD.0000000000032899","article-title":"Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment","volume":"102","author":"Alduais","year":"2023","journal-title":"Medicine"},{"key":"ref_5","unstructured":"WHO Classification of Tumours Editorial Board (2021). Thoracic Tumours. WHO Classification of Tumours, International Agency for Research on Cancer. [5th ed.]."},{"key":"ref_6","first-page":"415","article-title":"Molecular alterations of driver genes in non-small cell lung cancer: From diagnostics to targeted therapy","volume":"22","author":"Grodzka","year":"2023","journal-title":"EXCLI J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1053\/j.semdp.2021.04.001","article-title":"Updates in the molecular pathology of non-small cell lung cancer","volume":"38","author":"Paver","year":"2021","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jtho.2019.01.020","article-title":"Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience","volume":"14","author":"Behera","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.3390\/curroncol29070396","article-title":"Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer","volume":"29","author":"Ionescu","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e7162","DOI":"10.1002\/cam4.7162","article-title":"Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis","volume":"13","author":"Murakami","year":"2024","journal-title":"Cancer Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Wasiak, K., Ciunowicz, D., Kierasi\u0144ska-Ka\u0142ka, A., W\u0119gierska, M., Pacholczyk, M., Rieske, P., and Stoczy\u0144ska-Fidelus, E. (2025). The complex journey of targeting RAS in oncology. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14033-y"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.lungcan.2017.12.005","article-title":"A cross-sectional study examining the expression of splice variants K-RAS4A and K-RAS4B in advanced non-small-cell lung cancer patients","volume":"116","author":"Aran","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13045-022-01375-4","article-title":"Drugging KRAS: Current perspectives and state-of-art review","volume":"15","author":"Parikh","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12943-024-02216-3","article-title":"Targeting KRAS: From metabolic regulation to cancer treatment","volume":"24","author":"Shi","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e2023112118","DOI":"10.1073\/pnas.2023112118","article-title":"KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform","volume":"118","author":"Paniagua","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1042\/BST20160303","article-title":"Targeting the Ras palmitoylation\/depalmitoylation cycle in cancer","volume":"45","author":"Lin","year":"2017","journal-title":"Biochem. Soc. Trans."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/s41401-020-00542-y","article-title":"Post-translational modification of KRAS: Potential targets for cancer therapy","volume":"42","author":"Wang","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.csbj.2019.12.004","article-title":"The current understanding of KRAS protein structure and dynamics","volume":"18","author":"Pantsar","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Abdelkarim, H., Banerjee, A., Grudzien, P., Leschinsky, N., Abushaer, M., and Gaponenko, V. (2019). The Hypervariable Region of K-Ras4B Governs Molecular Recognition and Function. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225718"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"a031500","DOI":"10.1101\/cshperspect.a031500","article-title":"Ras-Specific GTPase-Activating Proteins-Structures, Mechanisms, and Interactions","volume":"9","author":"Scheffzek","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41392-023-01441-4","article-title":"Targeting small GTPases: Emerging grasps on previously untamable targets, pioneered by KRAS","volume":"8","author":"Yin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41392-025-02473-8","article-title":"Targeting KRAS mutations: Orchestrating cancer evolution and therapeutic challenges","volume":"10","author":"Choucair","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrc2960","article-title":"Ras superfamily GEFs and GAPs: Validated and tractable targets for cancer therapy?","volume":"10","author":"Vigil","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2016.12.001","article-title":"Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK","volume":"53","author":"Martinelli","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The Frequency of Ras Mutations in Cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Cuesta, C., Ar\u00e9valo-Alameda, C., and Castellano, E. (2021). The Importance of Being PI3K in the RAS Signaling Network. Genes, 12.","DOI":"10.3390\/genes12071094"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/s42003-025-08742-0","article-title":"RhoA allosterically activates phospholipase C\u03b5 via its EF hands","volume":"8","author":"Ohri","year":"2025","journal-title":"Commun. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.canlet.2007.09.003","article-title":"Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras","volume":"258","author":"Shi","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/ncb833","article-title":"Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism","volume":"4","author":"Lambert","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1038\/onc.2015.45","article-title":"An EGFR\/PI3K\/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis","volume":"34","author":"Zhu","year":"2015","journal-title":"Oncogene"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Newman, A.C., Scholefield, C.L., Kemp, A.J., Newman, M., McIver, E.G., Kamal, A., and Wilkinson, S. (2012). TBK1 kinase addiction in lung cancer cells is mediated via autophagy of Tax1bp1\/Ndp52 and non-canonical NF-\u03baB signalling. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050672"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.isci.2018.09.012","article-title":"A Potent and Selective ULK1 Inhibitor Suppresses Autophagy and Sensitizes Cancer Cells to Nutrient Stress","volume":"8","author":"Martin","year":"2018","journal-title":"iScience"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12943-024-02157-x","article-title":"The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer","volume":"23","author":"McDaid","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","article-title":"Oncogenic alterations in advanced NSCLC: A molecular super-highway","volume":"12","author":"Friedlaender","year":"2024","journal-title":"Biomark. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/s41417-024-00778-4","article-title":"Targeting KRASG12D mutation in non-small cell lung cancer: Molecular mechanisms and therapeutic potential","volume":"31","author":"Tang","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/1535-7163.MCT-21-0201","article-title":"Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer","volume":"20","author":"Judd","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_39","first-page":"67","article-title":"Management of KRAS-mutated non-small cell lung cancer","volume":"22","author":"Malhotra","year":"2024","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1611733","DOI":"10.3389\/pore.2024.1611733","article-title":"The rapidly changing field of predictive biomarkers of non-small cell lung cancer","volume":"30","year":"2024","journal-title":"Pathol. Oncol. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"oyaf153","DOI":"10.1093\/oncolo\/oyaf153","article-title":"KRAS mutated NSCLC: Past, present, and future directions in a rapidly evolving landscape","volume":"30","author":"Frisch","year":"2025","journal-title":"Oncologist"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.trecan.2017.08.006","article-title":"KRAS Alleles: The Devil Is in the Detail","volume":"3","author":"Haigis","year":"2017","journal-title":"Trends Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1158\/2159-8290.CD-22-0035","article-title":"Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention","volume":"12","author":"Johnson","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: Structure visualization for researchers, educators, and developers","volume":"30","author":"Pettersen","year":"2021","journal-title":"Protein Sci."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Markovi\u0107, F., Milin-Lazovi\u0107, J., Nikoli\u0107, N., Golubovi\u0107, A., Stjepanovi\u0107, M., and Konti\u0107, M. (2025). KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32060365"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"101106","DOI":"10.1016\/j.currproblcancer.2024.101106","article-title":"Current perspectives of KRAS in non-small cell lung cancer","volume":"51","author":"Harris","year":"2024","journal-title":"Curr. Probl. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Carnero-Gregorio, M., Perera-Gordo, E., de la Pe\u00f1a-Castro, V., Fern\u00e1ndez-G\u00f3mez, A., and Rodr\u00edguez-Cerdeira, C. (2026). Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing. Genes, 17.","DOI":"10.3390\/genes17020209"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41401-023-01194-4","article-title":"From bench to bedside: Current development and emerging trend of KRAS-targeted therapy","volume":"45","author":"Chen","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_49","first-page":"e60061","article-title":"KRAS as a Prognostic and Predictive Marker in Metastatic Non-Small Cell Lung Carcinoma: A Systematic Review","volume":"16","author":"Fatima","year":"2024","journal-title":"Cureus"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1007\/s12672-025-03569-x","article-title":"Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors","volume":"16","author":"Wang","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Karki, R., Chen, R., and Pan, S. (2025). Proteomic Perspectives on KRAS-Driven Cancers and Emerging Therapeutic Approaches. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32110614"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Karachaliou, A., Kotteas, E., Fiste, O., and Syrigos, K. (2024). Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer. Cancers, 16.","DOI":"10.3390\/cancers16081447"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Motta, L., Epistolio, S., Pankovics, J., Molinari, F., Pedrazzini, B., Valera, A., Giudici, L., Freguia, S., Patella, M., and Imbimbo, M. (2025). A Real-World Experience on the Efficacy of First-Line Treatment with Immune-Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression \u226550%: The Role of KRAS Mutations. Cancers, 17.","DOI":"10.3390\/cancers17243980"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Motta, L., Molinari, F., Pankovics, J., Pedrazzini, B., Valera, A., Epistolio, S., Giudici, L., Freguia, S., Patella, M., and Imbimbo, M. (2025). Prognostic Impact of KRAS-TP53 Co-Mutations in Patients with Early-Stage Non-Small Cell Lung Cancer: A Single-Center Retrospective Study. J. Clin. Med., 14.","DOI":"10.20944\/preprints202506.1558.v1"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"17588359261424770","DOI":"10.1177\/17588359261424770","article-title":"The relationship between genetic mutations and organ metastasis in non-small cell lung cancer","volume":"18","author":"Xue","year":"2026","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"737","DOI":"10.21037\/tlcr-20-958","article-title":"KRASG12C\/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (\u226550%) lung adenocarcinoma","volume":"10","author":"Frost","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","article-title":"Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer","volume":"24","author":"Arbour","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1158\/1078-0432.CCR-20-1825","article-title":"The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","article-title":"ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: An analysis of 1,683 patients with non-small cell lung cancer","volume":"19","author":"Gainor","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e06907","DOI":"10.7554\/eLife.06907","article-title":"Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma","volume":"4","author":"Unni","year":"2015","journal-title":"eLife"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jtho.2017.01.004","article-title":"ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer","volume":"12","author":"Lin","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/annonc\/mdz136","article-title":"Germline-focussed analysis of tumour-only sequencing: Recommendations from the ESMO Precision Medicine Working Group","volume":"30","author":"Mandelker","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1002\/cam4.2183","article-title":"Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF","volume":"8","author":"Zhuang","year":"2019","journal-title":"Cancer Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/omi.2020.0141","article-title":"In Silico Tools and Approaches for the Prediction of Functional and Structural Effects of Single-Nucleotide Polymorphisms on Proteins: An Expert Review","volume":"25","author":"Yazar","year":"2021","journal-title":"OMICS"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Ishaq, S., Ali, A., Habib, O., Usmani, S.A., Rehman, I.U., Aziz, A., Ali, Y., Ahmad, A., and Ullah, A. (2026). Pathogenic KRAS variants disrupt structure and dynamics: Insights from integrated computational analyses. PLoS ONE, 21.","DOI":"10.1371\/journal.pone.0341219"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"13362","DOI":"10.1021\/acsomega.3c00804","article-title":"In Silico Analysis of nsSNPs of Human KRAS Gene and Protein Modeling Using Bioinformatic Tools","volume":"8","author":"Xu","year":"2023","journal-title":"ACS Omega"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Wang, Q., Mehmood, A., Wang, H., Xu, Q., Xiong, Y., and Wei, D.Q. (2019). Computational Screening and Analysis of Lung Cancer Related Non-Synonymous Single Nucleotide Polymorphisms on the Human Kirsten Rat Sarcoma Gene. Molecules, 24.","DOI":"10.3390\/molecules24101951"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"110401","DOI":"10.1016\/j.ygeno.2022.110401","article-title":"Genetic determinants of lung cancer: Understanding the oncogenic potential of somatic missense mutations","volume":"114","author":"Dhakar","year":"2022","journal-title":"Genomics"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1089\/gtmb.2021.0219","article-title":"The Effect of the Kirsten Rat Sarcoma Viral Oncogene Homolog (Kras) Proto-Oncogene, GTPase Genetic Polymorphism on the Safety and Efficacy of Bevacizumab Combination Treatment Regimens for Patients with Nonsquamous, Non-Small Cell Lung Cancer with Brain Metastases","volume":"26","author":"Song","year":"2022","journal-title":"Genet. Test. Mol. Biomark."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"105701","DOI":"10.1016\/j.compbiomed.2022.105701","article-title":"Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genes","volume":"148","author":"Kumar","year":"2022","journal-title":"Comput. Biol. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1007\/s12094-017-1620-7","article-title":"KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer","volume":"19","author":"Sullivan","year":"2017","journal-title":"Clin. Transl. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4103\/0973-1482.147379","article-title":"rs61764370 polymorphism of Kras and risk of cancer in Caucasian population: A meta-analysis","volume":"12","author":"Zhang","year":"2016","journal-title":"J. Cancer Res. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"8535","DOI":"10.1158\/0008-5472.CAN-08-2129","article-title":"A SNP in a let-7 microRNA complementary site in the KRAS 3\u2032 untranslated region increases non-small cell lung cancer risk","volume":"68","author":"Chin","year":"2008","journal-title":"Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.lungcan.2009.09.008","article-title":"KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer","volume":"69","author":"Nelson","year":"2010","journal-title":"Lung Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.4314\/ahs.v20i3.35","article-title":"Association of Rs61764370 polymorphism within let-7 microRNA-binding site with lung cancer in Iranian population","volume":"20","author":"Farokhzad","year":"2020","journal-title":"Afr. Health Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.2147\/COPD.S83596","article-title":"A variant in 3\u2032-untranslated region of KRAS compromises its interaction with hsa-let-7g and contributes to the development of lung cancer in patients with COPD","volume":"10","author":"Hu","year":"2015","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"172","DOI":"10.29252\/JABR.05.04.07","article-title":"The Association Between KRAS rs712 Polymorphism Within let-7 microRNA-Binding Site and Lung Cancer in the Iranian Population","volume":"5","author":"Farokhzad","year":"2018","journal-title":"J. Appl. Biotechnol. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41698-025-01003-7","article-title":"Epigenetic regulators in cancer therapy and progression","volume":"9","author":"Marei","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"M\u00e1rton, \u00c9., Varga, A., Domoszlai, D., Bugly\u00f3, G., Bal\u00e1zs, A., Penyige, A., Balogh, I., Nagy, B., and Szil\u00e1gyi, M. (2025). Non-Coding RNAs in Cancer: Structure, Function, and Clinical Application. Cancers, 17.","DOI":"10.3390\/cancers17040579"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Liu, Y., Ding, W., Wang, J., Ao, X., and Xue, J. (2023). Non-coding RNAs in lung cancer: Molecular mechanisms and clinical applications. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1256537"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Suri, C., Swarnkar, S., Bhaskar, L., and Verma, H.K. (2024). Non-Coding RNA as a Biomarker in Lung Cancer. Non-Coding RNA, 10.","DOI":"10.3390\/ncrna10050050"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, J., Hayder, H., Zayed, Y., and Peng, C. (2018). Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00402"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"155222","DOI":"10.1016\/j.prp.2024.155222","article-title":"Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer","volume":"256","author":"Singh","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2005.01.014","article-title":"RAS is regulated by the let-7 microRNA family","volume":"120","author":"Johnson","year":"2005","journal-title":"Cell"},{"key":"ref_86","first-page":"312","article-title":"MiR-1205 functions as a tumor suppressor by disconnecting the synergy between KRAS and MDM4\/E2F1 in non-small cell lung cancer","volume":"9","author":"Yan","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1159\/000485491","article-title":"MiR-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRAS","volume":"44","author":"Fan","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/onc.2016.308","article-title":"Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p","volume":"36","author":"Seviour","year":"2017","journal-title":"Oncogene"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13046-019-1170-7","article-title":"Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression","volume":"38","author":"Jin","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/abbs\/gmv054","article-title":"MiR-181a-5p inhibits cell proliferation and migration by targeting Kras in non-small cell lung cancer A549 cells","volume":"47","author":"Ma","year":"2015","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1159\/000495835","article-title":"miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras\/MAPK Pathway","volume":"51","author":"Sun","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Ding, C., Xi, G., Wang, G., Cui, D., Zhang, B., Wang, H., Jiang, G., Song, J., Xu, G., and Wang, J. (2020). Exosomal Circ-MEMO1 Promotes the Progression and Aerobic Glycolysis of Non-small Cell Lung Cancer Through Targeting MiR-101-3p\/KRAS Axis. Front. Genet., 11.","DOI":"10.3389\/fgene.2020.00962"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3892\/ol.2010.164","article-title":"Clinical significance and the correlation of expression between Let-7 and K-ras in non-small cell lung cancer","volume":"1","author":"Xia","year":"2010","journal-title":"Oncol. Lett."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/0008-5472.CAN-04-0637","article-title":"Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival","volume":"64","author":"Takamizawa","year":"2004","journal-title":"Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"8309015","DOI":"10.1155\/2018\/8309015","article-title":"Prognostic Role of MicroRNAs in Human Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis","volume":"2018","author":"Lamichhane","year":"2018","journal-title":"Dis. Markers"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00432-009-0747-5","article-title":"The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice","volume":"136","author":"He","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1073\/pnas.0712321105","article-title":"Suppression of non-small cell lung tumor development by the let-7 microRNA family","volume":"105","author":"Kumar","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3892\/ijo.2013.2003","article-title":"Let-7g and miR-21 expression in non-small cell lung cancer: Correlation with clinicopathological and molecular features","volume":"43","author":"Capodanno","year":"2013","journal-title":"Int. J. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Pulliero, A., Mastracci, L., Tarantini, L., Khalid, Z., Bollati, V., and Izzotti, A. (2023). Let-7a Downregulation Accompanied by KRAS Mutation Is Predictive of Lung Cancer Onset in Cigarette Smoke-Exposed Mice. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411778"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Mishra, A.K., Mumtaz, N., and Misra, M.K. (2023). Identification of Candidate mRNA Genes and Their Potential MicroRNA Targets in Lung Cancer Induced by Smoking Tobacco. Front. Biosci., 15.","DOI":"10.31083\/j.fbs1504013"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e2400017","DOI":"10.1111\/boc.202400017","article-title":"Association of 3\u2032UTR variations of EGFR and KRAS oncogenes with clinical parameters in lung cancer tumours","volume":"116","author":"Bagci","year":"2024","journal-title":"Biol. Cell"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Izzotti, A., Coronel Vargas, G., Pulliero, A., Coco, S., Vanni, I., Colarossi, C., Blanco, G., Agodi, A., Barchitta, M., and Maugeri, A. (2021). Relationship between the miRNA Profiles and Oncogene Mutations in Non-Smoker Lung Cancer. Relevance for Lung Cancer Personalized Screenings and Treatments. J. Pers. Med., 11.","DOI":"10.3390\/jpm11030182"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ccr.2010.08.013","article-title":"Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21","volume":"18","author":"Hatley","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_104","first-page":"3539","article-title":"Overview upon miR-21 in lung cancer: Focus on NSCLC","volume":"75","author":"Magdo","year":"2018","journal-title":"Cell\/Mol. Life Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/17460441.2017.1263298","article-title":"MicroRNA-targeted therapeutics for lung cancer treatment","volume":"12","author":"Xue","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Forterre, A., Komuro, H., Aminova, S., and Harada, M. (2020). A Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies. Cancers, 12.","DOI":"10.3390\/cancers12071852"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1016\/j.ymthe.2023.09.015","article-title":"Comprehensive landscape and future perspective of long noncoding RNAs in non-small cell lung cancer: It takes a village","volume":"31","author":"Ao","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3892\/mmr.2025.13662","article-title":"CircRNA in non-small cell lung cancer: Potential biomarkers and therapeutic targets (Review)","volume":"32","author":"Wu","year":"2025","journal-title":"Mol. Med. Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"111349","DOI":"10.1016\/j.cellsig.2024.111349","article-title":"METTL3 -mediated m6A modification of circ_0000620 regulates cisplatin sensitivity and apoptosis in lung adenocarcinoma via the MiR-216b-5p\/KRAS axis","volume":"123","author":"Li","year":"2024","journal-title":"Cell. Signal"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"15455","DOI":"10.1038\/s41598-021-94671-x","article-title":"Kras-driven intratumoral heterogeneity triggers infiltration of M2 polarized macrophages via the circHIPK3\/PTK2 immunosuppressive circuit","volume":"11","author":"Katopodi","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/s41418-023-01160-x","article-title":"Long non-coding RNA HIF1A-As2 and MYC form a double-positive feedback loop to promote cell proliferation and metastasis in KRAS-driven non-small cell lung cancer","volume":"30","author":"Yang","year":"2023","journal-title":"Cell Death Differ."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e36026","DOI":"10.1097\/MD.0000000000036026","article-title":"Prognostic value of CASC15 and LINC01600 as competitive endogenous RNAs in lung adenocarcinoma: An observational study","volume":"102","author":"Zhou","year":"2023","journal-title":"Medicine"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"113003","DOI":"10.1016\/j.celrep.2023.113003","article-title":"Methylation of KRAS by SETD7 promotes KRAS degradation in non-small cell lung cancer","volume":"42","author":"Chiang","year":"2023","journal-title":"Cell Rep."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1038\/s44318-024-00146-w","article-title":"K128 ubiquitination constrains RAS activity by expanding its binding interface with GAP proteins","volume":"43","author":"Magits","year":"2024","journal-title":"EMBO J."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"114917","DOI":"10.1016\/j.celrep.2024.114917","article-title":"USP7 deubiquitinates KRAS and promotes non-small cell lung cancer","volume":"43","author":"Huang","year":"2024","journal-title":"Cell Rep."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41467-018-08115-8","article-title":"Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation","volume":"10","author":"Kano","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e202302094","DOI":"10.26508\/lsa.202302094","article-title":"A new ferrocene derivative blocks K-Ras localization and function by oxidative modification at His95","volume":"6","author":"Rehl","year":"2023","journal-title":"Life Sci. Alliance"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/1878-0261.13798","article-title":"Oncogenic mutant KRAS inhibition through oxidation at cysteine 118","volume":"19","author":"Petrini","year":"2025","journal-title":"Mol. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"100165","DOI":"10.1016\/j.lddd.2025.100165","article-title":"Structural classification of HDAC inhibitors and cancer treatment prospects: A review","volume":"22","author":"Ji","year":"2025","journal-title":"Lett. Drug Des. Discov."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/s12276-023-01091-0","article-title":"Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer","volume":"55","author":"Shin","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"80336","DOI":"10.18632\/oncotarget.12015","article-title":"SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status","volume":"7","author":"Song","year":"2016","journal-title":"Oncotarget"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"102957","DOI":"10.1016\/j.ctrv.2025.102957","article-title":"Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC)\u2013biology, clinical results and future directions","volume":"137","author":"Attili","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev-med-043024-115849","article-title":"Optimizing KRAS Therapeutics for Non-Small Cell Lung Cancer","volume":"77","author":"Lim","year":"2026","journal-title":"Annu. Rev. Med."},{"key":"ref_124","unstructured":"(2024, June 21). Clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1038\/s41591-025-03732-5","article-title":"Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer","volume":"31","author":"Skoulidis","year":"2025","journal-title":"Nat. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2026.01.001","article-title":"Emerging landscape of KRAS inhibitors in cancer treatment","volume":"44","author":"Riedl","year":"2026","journal-title":"Cancer Cell"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1200\/JCO.22.02524","article-title":"Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100","volume":"41","author":"Dy","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: A randomised, open-label, phase 3 trial","volume":"401","author":"Johnson","year":"2023","journal-title":"Lancet"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation","volume":"387","author":"Riely","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1078-0432.CCR-24-2310","article-title":"Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial","volume":"31","author":"Negrao","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.adg9652","article-title":"Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS","volume":"381","author":"Schulze","year":"2023","journal-title":"Science"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c02314","article-title":"Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers","volume":"68","author":"Cregg","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Mina, S.A., Shanshal, M., Leventakos, K., and Parikh, K. (2025). Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC). Cancers, 17.","DOI":"10.3390\/cancers17030353"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","article-title":"Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer","volume":"394","author":"Wolpin","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"108226","DOI":"10.1016\/j.phrs.2026.108226","article-title":"Daraxonrasib (RMC-6236) pharmacokinetics: Impact of transporters and drug-metabolizing enzymes on a first-in-class pan-RAS molecular glue","volume":"229","author":"Arguedas","year":"2026","journal-title":"Pharmacol. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"eads0239","DOI":"10.1126\/science.ads0239","article-title":"A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors","volume":"389","author":"Weller","year":"2025","journal-title":"Science"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.ccell.2025.05.016","article-title":"A first-in-class EGFR-directed KRAS G12V selective inhibitor","volume":"43","author":"Stanland","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_141","first-page":"1353","article-title":"Research progress and challenges in the treatment of oncogene-addicted non-small cell lung cancer","volume":"22","author":"Li","year":"2025","journal-title":"Cancer Biol. Med."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Huang, R., Gong, X., Du, J., Xu, G., Qian, J., Liao, G., Lin, Y., Pan, M., Zheng, B., and Yuan, W. (2026). Therapeutic strategies for KRAS G12C-mutant non-small cell lung cancer: From bench to bedside and beyond. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1704347"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"P05-01","DOI":"10.1158\/1535-7163.TARG-21-P05-01","article-title":"Abstract P05-01: A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors","volume":"20","author":"Ramalingam","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jtho.2025.01.006","article-title":"A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET)","volume":"20","author":"Akamatsu","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Rosas, D., Barad, P., Wright, J., and Raez, L. (2026). KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27146455"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1038\/s41467-023-42010-1","article-title":"KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors","volume":"14","author":"Lu","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1038\/s41467-022-32811-1","article-title":"Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen","volume":"13","author":"Poole","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cllc.2014.06.002","article-title":"Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation","volume":"15","author":"Chaft","year":"2014","journal-title":"Clin. Lung Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41419-024-06436-9","article-title":"Hedgehog signalling is involved in acquired resistance to KRASG12C inhibitors in lung cancer cells","volume":"15","author":"Lee","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","article-title":"Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC","volume":"13","author":"Negrao","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","article-title":"Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition","volume":"577","author":"Xue","year":"2020","journal-title":"Nature"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired Resistance to KRASG12C Inhibition in Cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Chour, A., Toffart, A.C., Berton, E., and Duruisseaux, M. (2024). Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1328728"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e148392","DOI":"10.1172\/jci.insight.148392","article-title":"Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer","volume":"6","author":"Padhye","year":"2021","journal-title":"JCI Insight"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/2159-8290.CD-23-0289","article-title":"Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma","volume":"14","author":"Li","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ccell.2024.01.012","article-title":"Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer","volume":"42","author":"Tong","year":"2024","journal-title":"Cancer Cell"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8194\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:20:44Z","timestamp":1789618844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":158,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188194"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188194","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}